WSD0922-FU

WSD0922-FU is an orally bioavailable, brain-penetrant, fourth-generation small molecule inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It is specifically designed to address resistance mutations such as EGFR C797S, which frequently emerge in patients with non-small cell lung cancer (NSCLC) following treatment with third-generation TKIs like osimertinib. WSD0922-FU is characterized by its high blood-brain barrier permeability, making it a potential therapeutic option for primary brain tumors, including glioblastoma and anaplastic astrocytoma, as well as for patients with NSCLC who have developed central nervous system (CNS) metastases. The compound is being developed by Wayshine Biopharm in collaboration with the Mayo Clinic and is currently undergoing clinical evaluation as both a monotherapy and in combination with other agents.